Trial Profile
A 2-Stage, Phase 2, Double-Masked, Randomized, Vehicle Controlled, Dose Response Trial Of PF-04217329 And The Marketed Formulation Of Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2021
Price :
$35
*
At a glance
- Drugs Taprenepag (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 May 2014 New trial record